About this Journal Submit a Manuscript Table of Contents

Advances in Prostate Cancer Research and Treatment

Call for Papers

Prostate cancer is one of the most commonly diagnosed cancers in men. Its etiology appears to be related to lifestyle patterns as well as genetic and epigenetic factors. Surgery, radiation therapy, hormonal manipulation, and chemotherapy remain the major milestones for the treatment of localized, locally advanced, or advanced prostate cancer, respectively. However, after these treatments, prostate cancer recurrence or progression is not uncommon. We now have a greater understanding of mechanisms sustaining prostate cancer progression and recurrence although we are aware that the improvement of oncological outcome of men who remain at high risk for systemic failure may be achieved translating the biological knowledge into clinical practice. Obviously, the information so-obtained could not be sufficient to unravel the molecular pathways that govern the mechanisms involved in the resistance to treatments. Hopefully, the knowledge of critical molecular events involved in these biological processes will allows us to identify unique signatures useful to inspire new therapeutic strategies for overcoming the problem of resistance to conventional treatments.

We invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts to understand the molecular pathology underlying prostate cancer recurrence and progression, the development of new combinational strategies to treat this condition, and the evaluation of oncological outcomes in a clinical setting. We are particularly interested in articles describing (1) new modalities for clinical characterization of prostate cancer and measuring outcomes from treatment trials; (2) advances in molecular genetics, diagnostic, and imaging; (3) current concepts in the treatment of Pca using ionizing radiation; and (4) measures of quality of life analysis and sexual health. Potential topics include, but are not limited to:

  • Conventional and molecular imaging
  • Radiation safety
  • Clinical and experimental radiobiology
  • Dosimetric analysis of radiation
  • Molecular determinants of sensitivity and resistance to treatments
  • Molecular determinants of tumor progression and recurrence
  • Regulatory role of sexual hormones
  • Nonsurgical treatments
  • Quality of life analysis and sexual medicine
  • Future strategies

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/pathology/procan/ according to the following timetable:

Manuscript DueFriday, 2 May 2014
First Round of ReviewsFriday, 25 July 2014
Publication DateFriday, 19 September 2014

Lead Guest Editor

  • Giovanni Luca Gravina, Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, Rome, Italy

Guest Editors

  • Lorenzo Livi, Radiotherapy Unit, Careggi Hospital, University of Florence, Italy
  • Andrea Maria Isidori, Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, Rome, Italy
  • David Sherris, Paloma Pharmaceuticals, Inc., Neillian Crescent, Jamaica Plain, MA 02130, USA